Two newer androgen deprivation therapies for late-stage prostate cancer include: Xtandi (enzalutamide) Erleada (apalutamide). Advancements in the treatment of late-stage prostate cancer are giving new ...

Get Instant Summarized Text (Gist) Artificial motors have been developed to mimic muscle proteins, converting chemical energy into mechanical work. These nanoscale rotary motors, embedded in ...

Announces encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with apalutamide in patients with mCRPC. Entered into clinical tr ...

The findings shed light on how socio-sexual preferences adapt for survival and health in mammals. Understanding these neural mechanisms could inform studies on social behavior and stress responses in ...

Key Laboratory of Eutrophication and Red Tide Prevention of Guangdong Higher Education Institutes, College of Life Science and Technology, Jinan University, Guangzhou 510632, China ...

They can now choose among 4 novel second-generation hormone therapies (the androgen receptor pathway inhibitors [ARPIs] abiraterone, enzalutamide, apalutamide, and darolutamide), 2 chemotherapy ...

Historically, investigations into the sensory mechanisms of olfactory receptors were often confined to behavioral characteristics in model organisms or the expression of related proteins and genes.

Apalutamide is under clinical development by Johnson & Johnson and currently in Phase II for Prostate Cancer. According to GlobalData, Phase II drugs for Prostate Cancer have a 23% phase transition ...

Androgen receptor pathway inhibitors (apalutamide [APA], enzalutamide [ENZ], abiraterone acetate plus prednisone [AAP]) combined with androgen-deprivation therapy (ADT) are effective life-prolonging ...